Clinical Trial Update: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread [Phase 3]

View source ↗

Summary

A Phase 3 study comparing sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Locally Advanced or Metastatic Unresectable Urothelial Cancer | Phase 3 | Status: COMPLETED